Eton Pharmaceuticals Stock Tumbles After FDA Rejects its Dehydrated Alcohol Injection Application For Methanol Poisoning


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


  • Eton Pharmaceuticals Inc (NASDAQ:ETONhas received a Complete Response Letter (CRL) from the FDA related to a marketing application for its dehydrated alcohol injection to treat methanol poisoning.
  • The CRL indicated that the FDA has completed its review of the application and has determined that the application cannot be approved in its present form.
  • A Pre-Approval Inspection of the product's European contract manufacturer is pending.
  • The company believes all other FDA questions raised in the letter can be fully addressed in a response in the coming months.
  • Price Action: ETON shares are down 29.3% at $6 in the premarket session on the last check Friday.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechNewsHealth CareFDAGeneralBriefs